UCB SA (OTCMKTS:UCBJY) Short Interest Update

UCB SA (OTCMKTS:UCBJY) was the recipient of a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 4,700 shares, a growth of 2,250.0% from the December 31st total of 200 shares. Based on an average daily volume of 13,700 shares, the short-interest ratio is presently 0.3 days.

UCB Stock Down 0.5 %

Shares of OTCMKTS:UCBJY traded down $0.48 during midday trading on Tuesday, hitting $98.22. The stock had a trading volume of 45,810 shares, compared to its average volume of 7,263. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. The business’s 50-day simple moving average is $96.95 and its 200-day simple moving average is $91.99. UCB has a 12 month low of $46.00 and a 12 month high of $100.66.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.